- Home
- RBOT vs YI Comparison
RBOT vs YI Comparison
Compare RBOT & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- YI
- Stock Information
- Founded
- RBOT 2014
- YI 2010
- Country
- RBOT United States
- YI China
- Employees
- RBOT N/A
- YI N/A
- Industry
- RBOT Medical Specialities
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- RBOT Health Care
- YI Consumer Staples
- Exchange
- RBOT Nasdaq
- YI Nasdaq
- Market Cap
- RBOT 61.4M
- YI 60.7M
- IPO Year
- RBOT N/A
- YI N/A
- Fundamental
- Price
- RBOT $6.18
- YI $6.42
- Analyst Decision
- RBOT Hold
- YI
- Analyst Count
- RBOT 1
- YI 0
- Target Price
- RBOT $7.00
- YI N/A
- AVG Volume (30 Days)
- RBOT 36.5K
- YI 13.5K
- Earning Date
- RBOT 08-12-2025
- YI 08-28-2025
- Dividend Yield
- RBOT N/A
- YI N/A
- EPS Growth
- RBOT N/A
- YI N/A
- EPS
- RBOT N/A
- YI N/A
- Revenue
- RBOT N/A
- YI $1,984,717,013.00
- Revenue This Year
- RBOT N/A
- YI N/A
- Revenue Next Year
- RBOT N/A
- YI N/A
- P/E Ratio
- RBOT N/A
- YI N/A
- Revenue Growth
- RBOT N/A
- YI N/A
- 52 Week Low
- RBOT $5.00
- YI $4.15
- 52 Week High
- RBOT $19.00
- YI $11.90
- Technical
- Relative Strength Index (RSI)
- RBOT 36.78
- YI 37.12
- Support Level
- RBOT $5.89
- YI $6.70
- Resistance Level
- RBOT $6.91
- YI $7.07
- Average True Range (ATR)
- RBOT 0.74
- YI 0.39
- MACD
- RBOT -0.10
- YI 0.00
- Stochastic Oscillator
- RBOT 6.29
- YI 23.36
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.